128 related articles for article (PubMed ID: 12379583)
21. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
[TBL] [Abstract][Full Text] [Related]
22. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
Nishimura T; Faul JL; Berry GJ; Vaszar LT; Qiu D; Pearl RG; Kao PN
Am J Respir Crit Care Med; 2002 Nov; 166(10):1403-8. PubMed ID: 12406854
[TBL] [Abstract][Full Text] [Related]
23. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis.
Chen MS; Xu FP; Wang YZ; Zhang GP; Yi Q; Zhang HQ; Luo JD
J Mol Cell Cardiol; 2004 Oct; 37(4):889-96. PubMed ID: 15380679
[TBL] [Abstract][Full Text] [Related]
24. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice.
Ogita H; Node K; Liao Y; Ishikura F; Beppu S; Asanuma H; Sanada S; Takashima S; Minamino T; Hori M; Kitakaze M
Hypertension; 2004 Feb; 43(2):237-42. PubMed ID: 14676219
[TBL] [Abstract][Full Text] [Related]
26. The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.
Pan XD; Zeng ZH; Liang LY; Luo JD; Xiao AY; Lai Q; Wen YH; Lu DF; Wang W; He ZC; He WK
Clin Exp Hypertens; 2011; 33(8):558-64. PubMed ID: 21957976
[TBL] [Abstract][Full Text] [Related]
27. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats.
Bhuiyan MS; Shioda N; Fukunaga K
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1606-14. PubMed ID: 17878225
[TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Xu X; Zhang L; Liang J
Mol Med Rep; 2013 Aug; 8(2):385-92. PubMed ID: 23799547
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
Weinberg EO; Schoen FJ; George D; Kagaya Y; Douglas PS; Litwin SE; Schunkert H; Benedict CR; Lorell BH
Circulation; 1994 Sep; 90(3):1410-22. PubMed ID: 8087951
[TBL] [Abstract][Full Text] [Related]
30. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat.
Ostman-Smith I
Br J Pharmacol; 1995 Nov; 116(6):2703-9. PubMed ID: 8590993
[TBL] [Abstract][Full Text] [Related]
31. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
Irukayama-Tomobe Y; Miyauchi T; Sakai S; Kasuya Y; Ogata T; Takanashi M; Iemitsu M; Sudo T; Goto K; Yamaguchi I
Circulation; 2004 Feb; 109(7):904-10. PubMed ID: 14967736
[TBL] [Abstract][Full Text] [Related]
32. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Senthil V; Chen SN; Tsybouleva N; Halder T; Nagueh SF; Willerson JT; Roberts R; Marian AJ
Circ Res; 2005 Aug; 97(3):285-92. PubMed ID: 16020756
[TBL] [Abstract][Full Text] [Related]
33. Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells.
Otsuki T; Sakaguchi H; Hatayama T; Fujii T; Tsujioka T; Sugihara T; Takata A; Hyodoh F; Eto M
Oncol Rep; 2004 May; 11(5):1053-8. PubMed ID: 15069546
[TBL] [Abstract][Full Text] [Related]
34. HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
Sala SG; Muñoz U; Bartolomé F; Bermejo F; Martín-Requero A
J Pharmacol Exp Ther; 2008 Jan; 324(1):352-9. PubMed ID: 17928568
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling.
Miura S; Matsuo Y; Saku K
Atherosclerosis; 2004 Aug; 175(2):235-43. PubMed ID: 15262179
[TBL] [Abstract][Full Text] [Related]
36. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway.
Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H
J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases.
Ghittoni R; Patrussi L; Pirozzi K; Pellegrini M; Lazzerini PE; Capecchi PL; Pasini FL; Baldari CT
FASEB J; 2005 Apr; 19(6):605-7. PubMed ID: 15677697
[TBL] [Abstract][Full Text] [Related]
39. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload.
Ito H; Hiroe M; Hirata Y; Fujisaki H; Adachi S; Akimoto H; Ohta Y; Marumo F
Circulation; 1994 May; 89(5):2198-203. PubMed ID: 8181145
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
